Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
SB-485232 will be administered as five daily intravenous (IV) infusions repeated every 28
days in adult subjects with advanced solid tumors or lymphomas. Subjects may receive up to 6
cycles of treatment unless progressive disease or unacceptable toxicity is noted. Three dose
levels of drug will be investigated. Safety evaluations, including blood sampling for various
laboratory tests, will be conducted. Additional blood samples will also be taken to measure
the amount of drug in the body at specific times.